ライフサイエンスコーパス: depressive disorder

1 rget symptoms" (e.g., depressive symptoms in depressive disorders).

2 onopharmacological strategies to treat major depressive disorder.

3 in subjects with bipolar disorder and major depressive disorder.

4 esting-state fMRI data from a study of major depressive disorder.

5 t evidence of overlap with bipolar and major depressive disorder.

6 CI: 1.01, 1.22; P = 0.027) and no history of depressive disorder.

7 n prediction of treatment response for major depressive disorder.

8 error, 0.06); P = 0.911), and no history of depressive disorder.

9 phenotype from depressive symptoms to major depressive disorder.

10 ion contributes to the pathogenesis of major depressive disorder.

11 ess (CUS), a widely accepted model for major depressive disorder.

12 odels of depression and in humans with major depressive disorder.

13 a node in the dysfunctional network of major depressive disorder.

14 nd glutamatergic deficit hypotheses of major depressive disorder.

15 to several consecutive treatments for major depressive disorder.

16 ated by p11, a protein associated with major depressive disorder.

17 atient population includes adults with major depressive disorder.

18 tween dosage and treatment response in major depressive disorder.

19 uct, face, and predictive validity for major depressive disorder.

20 SRIs appear slightly more effective in major depressive disorder.

21 iate in bipolar disorder, and least in major depressive disorder.

22 tinuum between depressive symptoms and major depressive disorder.

23 ble strategy for preventing relapse in major depressive disorder.

24 ng schizophrenia, bipolar disorder and major depressive disorder.

25 st positive predictive value for first-onset depressive disorder.

26 cacy of SSRIs for treating adults with major depressive disorder.

27 atures) are common in individuals with major depressive disorder.

28 might be efficacious in patients with major depressive disorder.

29 efficacy and tolerability of SSRIs for major depressive disorder.

30 1.44) to 1.40 (95% CI: 1.03; 1.90) for major depressive disorder.

31 need to identify novel treatments for major depressive disorder.

32 tivity specifically predicts future risk for depressive disorder.

33 ased glutamate levels in patients with major depressive disorder.

34 ffer novel strategies for treatment of major depressive disorder.

35 ant suicidal ideation in patients with major depressive disorder.

36 luating anti-inflammatory therapies in major depressive disorder.

37 potential target for the treatment of major depressive disorder.

38 ror stress-associated diseases such as major depressive disorder.

39 idepressant responses in patients with major depressive disorder.

40 to risk of inflammatory disorders and major depressive disorder.

41 , schizophrenia, bipolar disorder, and major depressive disorder.

42 induced behavioral disorders including major depressive disorder.

43 orders, including autism, anxiety, and major depressive disorders.

44 of innovative antidepressants to treat major depressive disorders.

45 further investigation with this compound in depressive disorders.

46 ny mental disorder, and 0.12 (0.05-0.20) for depressive disorders.

47 reat the most commonly occurring anxiety and depressive disorders.

48 he 193 children, 90 had a diagnosis of major depressive disorder; 116 children had 3 full waves of ne

49 ] years), suicide rates for the cohorts with depressive disorder (235.1 per 100000 person-years), bip

50 hological Outcome Profiles), and symptoms of depressive disorder (9-item Patient Health Questionnaire

51 s than half of patients suffering from major depressive disorder, a leading cause of disability world

52 en of significant medical conditions such as depressive disorders, a major cause of disability worldw

53 Major depressive disorder affects around 16 per cent of the wo

54 antidepressants to treat patients with major depressive disorder after discussing treatment effects,

55 were associated with inpatient diagnosis of depressive disorder (AHR, 2.0; 95% CI, 1.4-2.8; referenc

56 15.5 years old with no lifetime history of a depressive disorder, along with a biological parent for

57 58; 95% CI, -2.40 to -0.77), and symptoms of depressive disorder (AMD, -3.41; 95% CI, -4.49 to -2.34)

58 rs predictive of treatment outcomes in major depressive disorder among treatment-naive adults.

59 ull clinical response in patients with major depressive disorder, an illness associated with dysregul

60 on is reported, with 421 patients with major depressive disorder and 488 control subjects.

61 ical trial, adults (N=80) with current major depressive disorder and a score >/=4 on the Scale for Su

62 ts age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on the Mo

63 throughout the body and is involved in major depressive disorder and antidepressant response.

64 does not distinguish individuals with major depressive disorder and attention-deficit hyperactivity

65 suicide victims who had suffered from major depressive disorder and control subjects who had died fr

66 Lifetime major depressive disorder and depressive symptom scores were u

67 enome-level pleiotropy between CAD and major depressive disorder and for an association with single-n

68 positivity at baseline predicted first-onset depressive disorder and greater depressive symptom score

69 ample comprising 596 participants with major depressive disorder and healthy controls.

70 o be an efficacious antidepressant for major depressive disorder and posttraumatic stress disorder.

71 factors for psychiatric illnesses like major depressive disorder and posttraumatic stress disorder.

72 bility, neuroticism, bipolar disorder, major depressive disorder and schizophrenia (standardised beta

73 h schizophrenia, bipolar disorder, and major depressive disorder and to identify risk loci for PTSD.

74 ach in reducing the risk of relapse in major depressive disorder and to place these findings in the l

75 eatment and CAU in preventing anxiety and/or depressive disorders and improving depressive symptoms.

76 nd may be effective in the prevention of new depressive disorders and in preventing relapse.

77 l period is a time of high risk for onset of depressive disorders and is associated with substantial

78 e X syndrome, Rett syndrome, epilepsy, major depressive disorder, and autism spectrum disorder.

79 For women, anxiety disorders, major depressive disorder, and dysthymia were the most common.

80 disorders including bipolar disorder, major depressive disorder, and schizophrenia, all marked with

81 ubjects with SZ, bipolar disorder, and major depressive disorder, and the messenger RNA was subjected

82 ial personality disorder, anxiety disorders, depressive disorders, and a history of violence.

83 e seen in individuals with major depression, depressive disorders, and anxiety disorders, as well as

84 gnificant after adjusting for comorbid major depressive disorder, anxiety disorder, and substance use

85 occurrence of the following outcomes: major depressive disorder, anxiety disorder, smoking and alcoh

86 For men in both China and India, major depressive disorder, anxiety disorders, and alcohol depe

87 eatments for adolescents with unipolar major depressive disorder are associated with diagnostic remis

88 or the application of psychotherapy in major depressive disorder are discussed, with special referenc

89 Objective: To examine whether depressive disorders are prospectively associated with i

90 primarily include bipolar disorder and major depressive disorder, are the leading cause of disability

91 , in keeping with growing evidence for major depressive disorder as an early marker of cerebral neuro

92 Secondary outcomes included major depressive disorder as measured by the Patient Health Qu

93 Main Outcomes and Measures: Time to onset of depressive disorders, as defined by the DSM-IV, associat

94 in this study involving patients with major depressive disorder associated with subthreshold hypoman

95 of reward-related iFC, predicted onset of a depressive disorder at 3-year follow-up.

96 nctional connectivity at baseline to predict depressive disorder at follow-up in a community sample o

97 ), even after excluding participants who had depressive disorders at baseline (odds ratio=1.52, 95% C

98 ciated with experiencing an episode of major depressive disorder before the first magnetic resonance

99 first-listed diagnosis of a mental disorder (depressive disorder, bipolar disorder, schizophrenia, su

100 ge for adults with first-listed diagnoses of depressive disorder, bipolar disorder, schizophrenia, su

101 ive disorder, posttraumatic stress disorder, depressive disorders, bipolar disorder, schizophrenia, a

102 imer's disease, schizophrenia, autism, major depressive disorder, body mass index, intracranial volum

103 morphometric studies of patients with major depressive disorder, both antidepressant responders and

104 cation for treatment-naive adults with major depressive disorder by defining a neuroimaging biomarker

105 Predicting treatment response for major depressive disorder can provide a tremendous benefit for

106 Parents with recurrent major depressive disorder, co-parents, and offspring (aged 9-1

107 Patients with major depressive disorder completed two rtfMRI-nf sessions (18

108 3 class I was increased in bipolar and major depressive disorder, consistent with observations in sch

109 Depressive disorders (DDs), anxiety disorders (ADs), obs

110 ychic Experiences at 16.5 years of age), (3) depressive disorder (Development and Well-Being Assessme

111 ficacy of sertraline treatment in preventing depressive disorders following TBI.

112 rs to be efficacious to prevent the onset of depressive disorders following TBI.

113 rotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within

114 al of Mental Disorders IV criteria for major depressive disorder from primary care and psychological

115 The study included 188 patients with major depressive disorder from the National Institute of Menta

116 rials of CRF1 receptor antagonists for major depressive disorder, generalized anxiety disorder, and s

117 Major depressive disorder has been associated with dysregulati

118 ber of randomized controlled trials in major depressive disorder have employed a sequential model, wh

119 Many patients with major depressive disorder have treatment-resistant depression,

120 versus nonpharmacologic treatments for major depressive disorder in adults.

121 y 31, 2015, for the acute treatment of major depressive disorder in children and adolescents.

122 e susceptible to chronic stress and of major depressive disorder in humans.

123 ar disorder may differ from those with major depressive disorder in neural mechanisms underlying anti

124 d promising candidate for treatment of major depressive disorder in patients who have an inadequate r

125 care model for treatment of adolescent major depressive disorder in primary care settings.

126 d rank antidepressants and placebo for major depressive disorder in young people.

127 enomic basis of the likelihood of developing depressive disorder is a considerable challenge.

128 Major depressive disorder is associated with disturbed circadi

129 Major depressive disorder is associated with raised peripheral

130 Major depressive disorder is characterized by reduced reward-r

131 Major depressive disorder is increasingly recognized to involv

132 Major depressive disorder is one of the most common mental dis

133 ation 2) had 2-fold increased risk for major depressive disorder (MDD) (hazard ratio [HR], 2.02; 95%

134 Less than one-third of patients with major depressive disorder (MDD) achieve remission with their f

135 Converging evidence suggests that major depressive disorder (MDD) affects multiple large-scale b

136 Thirty-three outpatients with major depressive disorder (MDD) and 20 matched controls comple

137 Major depressive disorder (MDD) and alcohol dependence (AD) ar

138 We found increased prevalence of major depressive disorder (MDD) and anxiety disorders over tim

139 ar disorder (BD), schizophrenia (SCZ), major depressive disorder (MDD) and autism spectrum disorder (

140 nce underlying the association between major depressive disorder (MDD) and cardio-metabolic diseases

141 receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls.

142 urthermore, p11 has been implicated in major depressive disorder (MDD) and in the actions of antidepr

143 The association between major depressive disorder (MDD) and obesity may stem from shar

144 Major depressive disorder (MDD) and other mood disorders remai

145 so observed a shared genetic basis for major depressive disorder (MDD) and schizophrenia (P < 1 x 10(

146 Major depressive disorder (MDD) and schizophrenia (SZ) are con

147 It is strongly associated with major depressive disorder (MDD) and several other psychiatric

148 uggests that long-term trajectories of major depressive disorder (MDD) are heterogeneous.

149 The molecular mechanisms underlying major depressive disorder (MDD) are largely unknown.

150 Evidence-based treatments for major depressive disorder (MDD) are not very successful in imp

151 The neuro-anatomical substrates of major depressive disorder (MDD) are still not well understood,

152 ciated with an increased likelihood of major depressive disorder (MDD) as well as suicidal thoughts a

153 We used polygenic risk scores for major depressive disorder (MDD) calculated from the results of

154 esponse to antidepressant treatment in major depressive disorder (MDD) cannot be predicted currently,

155 vestigated intrinsic brain networks in major depressive disorder (MDD) during a depressive episode an

156 tes to or underlies the development of major depressive disorder (MDD) during this sensitive period.

157 Research into the pathophysiology of major depressive disorder (MDD) has focused largely on individ

158 Although major depressive disorder (MDD) has low heritability, a genome

159 search for genetic variants underlying major depressive disorder (MDD) has not yet provided firm lead

160 Schizophrenia, bipolar disorder and major depressive disorder (MDD) have all been associated with

161 The clinical diagnosis and symptoms of major depressive disorder (MDD) have been closely associated w

162 red grey and white matter structure in Major Depressive Disorder (MDD) have been inconsistent.

163 Patients with major depressive disorder (MDD) have clinically relevant, sign

164 Studies of patients with major depressive disorder (MDD) have consistently reported red

165 Both bipolar disorder (BD) and major depressive disorder (MDD) have high morbidity and share

166 me-wide association studies (GWASs) of major depressive disorder (MDD) have identified few significan

167 nosine monophosphate (cAMP) cascade in major depressive disorder (MDD) have noted that the cAMP casca

168 The syndromic heterogeneity of major depressive disorder (MDD) hinders understanding of the e

169 Heterogeneity of major depressive disorder (MDD) illness course complicates cli

170 Major depressive disorder (MDD) in the elderly is a risk facto

171 igated NAc structural abnormalities in major depressive disorder (MDD) in two cohorts.

172 Major depressive disorder (MDD) is a complex and heterogeneous

173 Major depressive disorder (MDD) is a debilitating condition th

174 Major depressive disorder (MDD) is a debilitating mental illne

175 Major depressive disorder (MDD) is a disabling mood disorder,

176 Major depressive disorder (MDD) is a leading cause of disease

177 Major depressive disorder (MDD) is a prevalent psychiatric con

178 Major depressive disorder (MDD) is a recurring psychiatric ill

179 Major depressive disorder (MDD) is a substantial burden to pat

180 Major depressive disorder (MDD) is among the leading causes of

181 on-human animal research suggests that Major Depressive Disorder (MDD) is associated with abnormaliti

182 Major depressive disorder (MDD) is associated with deficits in

183 Major depressive disorder (MDD) is associated with reduced con

184 Major depressive disorder (MDD) is characterized by abnormal r

185 Major depressive disorder (MDD) is clinically, and likely path

186 Major depressive disorder (MDD) is common among children and a

187 Early-onset major depressive disorder (MDD) is common in individuals at hi

188 , evidence for leptin dysregulation in major depressive disorder (MDD) is conflicting.

189 Its relationship with major depressive disorder (MDD) is of particular importance.

190 Major depressive disorder (MDD) is predicted to be the second

191 Major depressive disorder (MDD) is prevalent among patients wi

192 Major depressive disorder (MDD) is the second largest cause of

193 criteria for mood disorders including major depressive disorder (MDD) largely ignore biological fact

194 he heterogeneity of genetic effects on major depressive disorder (MDD) may be partly attributable to

195 Limited successes of gene finding for major depressive disorder (MDD) may be partly due to phenotypi

196 Major depressive disorder (MDD) often emerges during adolescen

197 ct of daily stressors and a history of major depressive disorder (MDD) on inflammatory responses to h

198 cts who met DSM-IV criteria for either major depressive disorder (MDD) or bipolar disorder I/II and w

199 A channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks.

200 Major depressive disorder (MDD) patients display a common but

201 ns of brain functional connectivity in major depressive disorder (MDD) patients with suicidal ideatio

202 ccumbens (NAcc) have been reported for major depressive disorder (MDD) patients.

203 ural brain alterations associated with major depressive disorder (MDD) remains unresolved.

204 Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently availab

205 BDD) versus depressed individuals with major depressive disorder (MDD) versus healthy control subject

206 and mu-opioid receptor availability in major depressive disorder (MDD) volunteers.

207 ressant medication in outpatients with major depressive disorder (MDD) was examined in a 3-site, 8-we

208 50 patients with FEP, 50 patients with major depressive disorder (MDD), 50 patients with post-traumat

209 Human major depressive disorder (MDD), along with related mood disor

210 inflammation is often associated with major depressive disorder (MDD), and immunological biomarkers

211 -posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and the anxiety disorders-for

212 h major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD), and sc

213 neuropsychiatric disorders, including major depressive disorder (MDD), bipolar disorder, anxiety dis

214 ividuals with a principal diagnosis of major depressive disorder (MDD), bipolar disorder, or schizoaf

215 Millions of patients suffer from major depressive disorder (MDD), but many do not respond to se

216 ings in stress disorders, particularly major depressive disorder (MDD), highlighting insights from po

217 ed the relative importance of atypical major depressive disorder (MDD), nonatypical MDD, and dysthymi

218 vidence supporting the heritability of major depressive disorder (MDD), previous genome-wide studies

219 Major depressive disorder (MDD), schizophrenia (SCZ) and bipol

220 have been investigated as treatment of major depressive disorder (MDD), their comparative efficacy an

221 ate, well-demonstrated heritability of major depressive disorder (MDD), there has been limited succes

222 ral network functional connectivity in major depressive disorder (MDD).

223 ers, such as bipolar disorder (BD) and major depressive disorder (MDD).

224 tidepressant efficacy in patients with major depressive disorder (MDD).

225 n antidepressants for the treatment of major depressive disorder (MDD).

226 is one of the most common symptoms in major depressive disorder (MDD).

227 a-3 (n-3) fatty acids in subjects with major depressive disorder (MDD).

228 in stress-related illnesses including major depressive disorder (MDD).

229 ment of psychiatric diseases including major depressive disorder (MDD).

230 idine neurogenic compound for treating major depressive disorder (MDD).

231 idence for its efficacy in nonseasonal major depressive disorder (MDD).

232 yet to be reported in individuals with major depressive disorder (MDD).

233 alteration in patients diagnosed with major depressive disorder (MDD).

234 A reduction in NAc of individuals with major depressive disorder (MDD).

235 ADs) are the most common treatment for major depressive disorder (MDD).

236 -related disorders such as anxiety and major depressive disorder (MDD).

237 idence supports a role for dopamine in major depressive disorder (MDD).

238 een observed frequently in adults with major depressive disorder (MDD); however, results have been in

239 At baseline, 4853 veterans (19%) with major depressive disorder (MDD; International Classification o

240 = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07) and s

241 = 0.82, standard error (s.e.) = 0.03), major depressive disorder (MDD; r g = 0.69, s.e. = 0.07) and s

242 elop and test treatment predictors for major depressive disorders (MDDs), whereas imaging markers can

243 impairments in patients suffering from major depressive disorders (MDDs), yet the underlying physiopa

244 with either bipolar disorder (N=34) or major depressive disorder (N=69).

245 with either bipolar disorder (N=34) or major depressive disorder (N=69).

246 25 adults from five diagnostic groups (major depressive disorder, N=32; bipolar disorder, N=50; schiz

247 eractivity disorder, bipolar disorder, major depressive disorder, neuroticism, schizophrenia and verb

248 d young adults with moderate to severe major depressive disorder, none of whom were being treated wit

249 social interaction behaviors reminiscent of depressive disorders observed in human patients with dis

250 lso found between any 12-month DUD and major depressive disorder (odds ratio [OR], 1.3; 95% CI, 1.09-

251 strength predicted increased risk for future depressive disorder (odds ratio=1.54, 95% CI=1.09-2.18),

252 Depressive disorders often run in families, which, in ad

253 3, 2001, and Jan 31, 2014, with either major depressive disorder or bipolar disorder who were enrolle

254 In patients with major depressive disorder or bipolar disorder, abnormalities i

255 (D3) were measured in 51 patients with major depressive disorder or bipolar disorder.

256 ciation studies that focused on either major depressive disorder or depressive symptoms with mostly n

257 S, 1.08; 95% CI, 0.98-1.19; R(2) = 0.001) or depressive disorder (OR per SD increase in PRS, 1.02; 95

258 t not schizophrenia, bipolar disorder, major depressive disorder, or attention-deficit/hyperactivity

259 ymptoms within 24 hours in a subset of major depressive disorder patients.

260 w-up and the proportion meeting criteria for depressive disorder (PHQ-9 score >/=10) at 4- and 12-mon

261 cluding obsessive-compulsive disorder, major depressive disorder, posttraumatic stress disorder, and

262 on copy number variants (CNV) with recurrent depressive disorder (RDD).

263 At least 15% of cases of major depressive disorder remain refractory to treatment.

264 Not all patients with major depressive disorder respond to adequate pharmacological

265 ), bipolar disorder (BD) and recurrent major depressive disorder (rMDD) are common psychiatric illnes

266 Remitted patients with major depressive disorder (rMDD) often report more fluctuation

267 Newly diagnosed recurrent depressive disorder (RR 1.61; 95%CI 1.55-1.68), anxiety

268 l of 154 medication-free patients with major depressive disorder seeking treatment at two university

269 mon but variable diagnostic markers in major depressive disorder: some depressed individuals manifest

270 ychiatric controls (CON, N=29), DSM-IV major depressive disorder suicides (MDD-S, N=21) and MDD non-s

271 key strategy to reduce the treatment gap for depressive disorders, the leading mental health disorder

272 logic Treatment of Adult Patients with Major Depressive Disorder." The evidence review done for the g

273 kidney disease, low back and neck pain, and depressive disorders; the latter three were not among th

274 idepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a

275 f 25 patients with treatment-resistant major depressive disorder (TRD) who participated in an Institu

276 g a predominantly male population with major depressive disorder unresponsive to antidepressant treat

277 The SNP-based heritability of major depressive disorder was 0.21 (SE = 0.02), the SNP-based

278 Prevalence of major depressive disorder was 2.2% (95% UI 1.5-2.8) in Chinese

279 Prevalence of major depressive disorder was 3.3% (2.3-4.1) in Chinese women

280 Major depressive disorder was diagnosed in 22 (4%) participant

281 herapy in the treatment of adults with major depressive disorder were considered for inclusion in the

282 Forty-nine individuals diagnosed with major depressive disorder were enrolled with intent to treat i

283 Two patient groups with acute major depressive disorder were included.

284 1-17 years) with a diagnosis of DSM IV major depressive disorder were randomly assigned (1:1:1), via

285 Adult outpatients with major depressive disorder were randomly assigned to open or pl

286 METHOD: Adult outpatients with major depressive disorder were randomly assigned to open or pl

287 Lifetime subtypes of depressive disorders were determined using a structured

288 Depressive disorders were the primary psychiatric issue

289 aged 18 to 65 years, met criteria for major depressive disorder, were free of psychotropic medicatio

290 oms, but who did not meet criteria for major depressive disorder, were randomly assigned (1:1), via c

291 linergic signaling are associated with major depressive disorder, whereas pre-clinical studies have i

292 olar disorder is often misdiagnosed as major depressive disorder, which leads to inadequate treatment

293 nt of postpartum women experience anxiety or depressive disorders, which can have detrimental effects

294 ABAergic deficits may causally contribute to depressive disorders, while antidepressant therapies may

295 In participants with major depressive disorder who are trained to upregulate their

296 the large portion of older adults with major depressive disorder who do not respond to first-line pha

297 atients meeting DSM-IV-TR criteria for major depressive disorder who presented with two or three prot

298 ircuitry and behavior in patients with major depressive disorder will also be presented.

299 e efficacy and safety of lurasidone in major depressive disorder with mixed features.

300 maging Genetics through Meta-Analysis) Major Depressive Disorder Working Group on cortical structural